Phase II study of pembrolizumab and lenvatinib in advanced well-differentiated neuroendocrine tumors
The purpose of this study is to: - Assess overall radiographic response rate (ORR) which is the portion of patients with a tumor size reduction of a predefined amount for a minimum time period - Assess progression-free survival (PFS) - Test the safety and tolerability of pembrolizumab in combination with lenvatinib
Objective: To assess the overall radiographic response rate (ORR) associated with pembrolizumab in patients with advanced, progressive high-grade and/or poorly differentiated extrapulmonary neuroendocrine cancers. Objective: To assess progression-free survival (PFS) in this population based on RECIST 1.1 and irRECIST. Objective: To assess duration of response (DOR) by RECIST 1.1. Objective: To assess overall survival (OS) in this population. Objective: To assess safety and tolerability.
Immunotherapy; Therapy (NOS)
E7080 (Lenvatinib); Lenvatinib (Lenvima); Pembrolizumab (Keytruda)
Back to top
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate button below. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.